Crescita Therapeutics Inc.
CRRTF
$0.56
$0.00-0.85%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 16.75M | 15.16M | 15.82M | 14.54M | 13.02M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 16.75M | 15.16M | 15.82M | 14.54M | 13.02M |
| Cost of Revenue | 8.08M | 7.30M | 8.19M | 7.54M | 7.15M |
| Gross Profit | 8.66M | 7.86M | 7.63M | 7.00M | 5.87M |
| SG&A Expenses | 8.66M | 7.75M | 7.38M | 7.52M | 7.59M |
| Depreciation & Amortization | 420.20K | 402.60K | 475.80K | 425.80K | 392.90K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.58M | 15.87M | 16.44M | 15.90M | 15.57M |
| Operating Income | -836.00K | -709.50K | -627.70K | -1.37M | -2.55M |
| Income Before Tax | -214.10K | -29.40K | 348.40K | -957.90K | -2.21M |
| Income Tax Expenses | 6.50K | 6.50K | -10.00K | -10.00K | -10.00K |
| Earnings from Continuing Operations | -0.22 | -0.04 | 0.36 | -0.95 | -2.20 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -220.60K | -35.90K | 358.40K | -947.90K | -2.20M |
| EBIT | -836.00K | -709.50K | -627.70K | -1.37M | -2.55M |
| EBITDA | 167.40K | 261.60K | 320.50K | -471.20K | -1.69M |
| EPS Basic | -0.01 | 0.00 | 0.02 | -0.05 | -0.11 |
| Normalized Basic EPS | 0.02 | 0.02 | 0.02 | -0.03 | -0.07 |
| EPS Diluted | -0.01 | 0.00 | 0.02 | -0.05 | -0.12 |
| Normalized Diluted EPS | 0.01 | 0.02 | 0.02 | -0.03 | -0.07 |
| Average Basic Shares Outstanding | 75.00M | 75.41M | 75.92M | 76.36M | 76.87M |
| Average Diluted Shares Outstanding | 75.11M | 75.53M | 76.04M | 76.46M | 76.87M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |